Broadfin Capital’s Arcturus Therapeutics ARCT Stock Holding History

Broadfin Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-173,806	Closed	-$1.39M	–	55
2017 Q1	$1.39M	Sell	173,806 -120,066	-41%	-$1.11M	0.17%	48
2016 Q4	$4.32M	Buy	293,872 +1,379	+0.5%	+$20.6K	0.48%	46
2016 Q3	$5.06M	Buy	292,493 +70,049	+31%	+$2.26M	0.45%	55
2016 Q2	$6.99M	Hold	222,444	–	–	0.68%	38
2016 Q1	$5.9M	Hold	222,444	–	–	0.57%	46
2015 Q4	$9.78M	Hold	222,444	–	–	0.6%	46
2015 Q3	$9.4M	Sell	222,444 -3,243	-1%	-$171K	0.52%	50
2015 Q2	$10.3M	Buy	225,687 +3,399	+2%	+$156K	0.56%	45
2015 Q1	$8.76M	Buy	+222,288	New	+$9.78M	0.68%	41

Other funds holding ARCT

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Broadfin Capital's ARCT Position: Q2 2017 in Review

Broadfin Capital sold out of Arcturus Therapeutics (ARCT) in Q2 2017, closing a stake of 173,806 shares — an estimated $1.39M sold.

Broadfin Capital first reported a position in ARCT in Q1 2015 and held it in 9 quarters. The position peaked at $10.3M in Q2 2015. 23 funds tracked by Wall St. Rank hold ARCT as of Q2 2017.

Broadfin Capital reported no remaining Arcturus Therapeutics position as of Q2 2017 after selling out during the quarter.
Broadfin Capital sold 173,806 Arcturus Therapeutics shares in Q2 2017, an estimated $1.39M.
Broadfin Capital first reported a position in Arcturus Therapeutics in Q1 2015 and held it in 9 quarters.
Broadfin Capital's Arcturus Therapeutics position peaked at $10.3M in Q2 2015.
23 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2017.

Based on Broadfin Capital's 13F filing for Q2 2017, filed 14 Aug 2017.